ftInvstr
AMBALALSA · Healthcare ₹43.5 -0.02% Mkt Cap ₹328 Cr

AMBALALSA

Healthcare Drug Manufacturers - Specialty & Generic
₹43.5
-0.02% today · 30d +0.44%
as of 2026-09-04
Price · Daily Candles
“Ambalal Sarabhai faces valuation questions despite low-risk profile.”
Ambalal Sarabhai Enterprises trades at a TTM P/E of 23.88 and a P/B of 1.76, indicating a potentially reasonable valuation given its very low risk score of 90/100. However, with an EPS of ₹1.36 and a market cap of ₹248 Cr, its small scale might temper enthusiasm.
BULL CASE
+The company demonstrates a very low risk profile, scoring 90 out of 100 on our business risk axis.
+Valuation appears reasonable with a P/E (TTM) of 23.88 and a P/B of 1.76.
+Despite market volatility, the stock is only -9.77% off its 52-week high of ₹36.45.
+The one-week return stands at a positive 4.41%.
BEAR CASE
The stock has a market capitalization of just ₹248 Cr, classifying it as a micro-cap.
Despite positive short-term returns, the stock has seen a -6.7% decline over the past month.
Profit margin is relatively low at 5.16%.
The EPS (TTM) is a modest ₹1.36.
◇ Sector Position
Ambalal Sarabhai's TTM P/E of 23.88 is lower than peers like Sun Pharma (40.41 P/E) and Divis Labs (69.81 P/E), but its ROCE data is unavailable for a direct benchmark against the sector's 21-27% range.
PEERPEROCE %
AMBALALSA23.88
SUNPHARMA40.4122.46
DIVISLAB69.8121.47
CIPLA29.5225.09
+ 2 more peers — sign in to view
72
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
Valuation REASONABLE 60
Growth
Profitability
Technicals NEUTRAL 67
Risk LOW 90
Key Stats
TTM PE
23.88
P/B
1.76
52W HIGH
₹49.98
OFF HIGH
-12.97%
MKT CAP
₹328 Cr
◉ Active Signals
MACDNeutral-0.6016
RSI(14)Neutral53.65
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold AMBALALSA and at what entry.

Sign up freeSign in